ABVC BioPharma, Inc.
ABVC
$0.742
-$0.1725-18.86%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 2,289.94% | 1,819.67% | -99.06% | -99.63% | -62.41% |
| Total Other Revenue | -41.51% | -- | -- | -- | -- |
| Total Revenue | 2,348.43% | 1,819.67% | -99.06% | -99.63% | -62.41% |
| Cost of Revenue | -98.99% | -99.73% | -99.50% | -47.55% | 176.64% |
| Gross Profit | 2,939.42% | 274.89% | -98.68% | -142.34% | -143.49% |
| SG&A Expenses | -84.94% | -34.69% | 105.97% | -10.63% | -41.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -256.48% | -- | -- | -- | -- |
| Total Operating Expenses | -85.22% | -50.28% | 69.36% | -47.24% | -41.95% |
| Operating Income | 103.08% | 55.48% | -80.69% | 37.39% | 41.72% |
| Income Before Tax | 96.03% | 38.05% | -109.84% | 10.84% | 10.69% |
| Income Tax Expenses | 140.00% | -235.74% | -- | -81.79% | -123.81% |
| Earnings from Continuing Operations | 96.01% | 45.03% | -109.84% | 26.02% | 10.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -203.36% | 402.90% | -34.69% | 160.28% | -29.43% |
| Net Income | 94.38% | 55.26% | -115.66% | 36.04% | 10.46% |
| EBIT | 103.08% | 55.48% | -80.69% | 37.39% | 41.72% |
| EBITDA | 103.42% | 55.95% | -81.24% | 37.50% | 41.82% |
| EPS Basic | 98.17% | 86.93% | 26.73% | 68.32% | 28.06% |
| Normalized Basic EPS | 97.83% | 86.86% | 25.48% | 68.03% | 27.78% |
| EPS Diluted | 97.56% | 86.84% | 26.73% | 68.02% | 28.07% |
| Normalized Diluted EPS | 97.83% | 86.86% | 25.48% | 68.03% | 27.78% |
| Average Basic Shares Outstanding | 205.90% | 242.17% | 194.36% | 101.91% | 24.48% |
| Average Diluted Shares Outstanding | 205.90% | 242.17% | 194.36% | 101.91% | 24.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
